ArticleBMC medicine2022

Increased blood-based intratumor heterogeneity (bITH) is associated with unfavorable outcomes of immune checkpoint inhibitors plus chemotherapy in non-small cell lung cancer.

Juan Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.